Lucas Grecco Hoffmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Grecco Hoffmann has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Amanda Canato Ferracini
Postgraduate Program in Tocogynecology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publicationDeayra Emyle Figueira
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, Women’s Hospital Prof Dr José Aristodemo Pinotti (CAISM), State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publicationGeisilene Russano de Paiva Silva
Laboratory of Molecular and Investigative Pathology – LAPE, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publicationJosé Vassallo
Laboratory of Investigative Pathology, CIPED, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publicationKarina da Silva Araujo
Multipat Anatomic Pathology Laboratory, Campinas, Brazil
1 shared publicationLuis Otavio Sarian
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, Women’s Hospital Prof Dr José Aristodemo Pinotti (CAISM), State University of Campinas (UNICAMP), Campinas, Brazil
1 shared publication
Latest Publications
- Open Access
- 18 November 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma
Herein it was evaluated the impact of PD-L1 immunohistochemical expression and stromal tumor-infiltrating lymphocyte (sTIL) counts in pretreatment needle core biopsy on response to neoadjuvant chemotherapy (NACT) for patients with breast carcinomas (BC). In 127 paired pre- and post-NACT BC specimens, immunohistochemical expression of PD-L1 was evaluated in stroma and in neoplastic cells. In the same samples sTILs were semi-quantified in tumor stroma. Post-NACT specimens were histologically rated as having residual cancer burden (RCB of any degree), or with complete pathological response (pCR). PD-L1 expression and higher sTIL counts were associated with histological grade 3 BC. PD-L1 expression was also associated with the non-luminal-HER2+ and triple negative immunohistochemical profiles of BC. Pathological complete response was associated with histological grade 3 tumors, and with the non-luminal-HER2+ and triple negative profiles. Additionally, our results support an association between PD-L1 expression and pCR to NACT. It was also observed that there is a trend to reduction of sTIL counts in the post-NACT specimens of patients with pCR. Of note, PD-L1 was expressed in half of the hormone receptor positive cases, a finding that might expand the potential use of immune checkpoint inhibitors for BC patients.
- 18 November 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Open AccessEvaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma
Herein it was evaluated the impact of PD-L1 immunohistochemical expression and stromal tumor-infiltrating lymphocyte (sTIL) counts in pretreatment needle core biopsy on response to neoadjuvant chemotherapy (NACT) for patients with breast carcinomas (BC). In 127 paired pre- and post-NACT BC specimens, immunohistochemical expression of PD-L1 was evaluated in stroma and in neoplastic cells. In the same samples sTILs were semi-quantified in tumor stroma. Post-NACT specimens were histologically rated as having residual cancer burden (RCB of any degree), or with complete pathological response (pCR). PD-L1 expression and higher sTIL counts were associated with histological grade 3 BC. PD-L1 expression was also associated with the non-luminal-HER2+ and triple negative immunohistochemical profiles of BC. Pathological complete response was associated with histological grade 3 tumors, and with the non-luminal-HER2+ and triple negative profiles. Additionally, our results support an association between PD-L1 expression and pCR to NACT. It was also observed that there is a trend to reduction of sTIL counts in the post-NACT specimens of patients with pCR. Of note, PD-L1 was expressed in half of the hormone receptor positive cases, a finding that might expand the potential use of immune checkpoint inhibitors for BC patients.